CN113574072B - 靶向C5aR的抗体 - Google Patents

靶向C5aR的抗体 Download PDF

Info

Publication number
CN113574072B
CN113574072B CN202080021131.1A CN202080021131A CN113574072B CN 113574072 B CN113574072 B CN 113574072B CN 202080021131 A CN202080021131 A CN 202080021131A CN 113574072 B CN113574072 B CN 113574072B
Authority
CN
China
Prior art keywords
seq
region
antibody
human
leu
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN202080021131.1A
Other languages
English (en)
Chinese (zh)
Other versions
CN113574072A (zh
Inventor
J·诺伊格鲍尔
B·巴赫勒尔-科内茨基
T·赫尔曼
W·埃利斯
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Morphosys GmbH
Original Assignee
Morphosys GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Morphosys GmbH filed Critical Morphosys GmbH
Publication of CN113574072A publication Critical patent/CN113574072A/zh
Application granted granted Critical
Publication of CN113574072B publication Critical patent/CN113574072B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
    • C07K2317/14—Specific host cells or culture conditions, e.g. components, pH or temperature
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/35—Valency
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/524—CH2 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/72—Increased effector function due to an Fc-modification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
CN202080021131.1A 2019-03-14 2020-03-13 靶向C5aR的抗体 Active CN113574072B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP19162759 2019-03-14
EP19162759.5 2019-03-14
PCT/EP2020/056754 WO2020182974A1 (en) 2019-03-14 2020-03-13 Antibodies targeting c5ar

Publications (2)

Publication Number Publication Date
CN113574072A CN113574072A (zh) 2021-10-29
CN113574072B true CN113574072B (zh) 2023-12-12

Family

ID=65812165

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202080021131.1A Active CN113574072B (zh) 2019-03-14 2020-03-13 靶向C5aR的抗体

Country Status (14)

Country Link
US (3) US20220135658A1 (https=)
EP (1) EP3938393A1 (https=)
JP (2) JP7617012B2 (https=)
KR (1) KR20210141988A (https=)
CN (1) CN113574072B (https=)
AU (1) AU2020235263A1 (https=)
BR (1) BR112021017860A2 (https=)
CA (1) CA3132771A1 (https=)
IL (1) IL286238A (https=)
MA (1) MA55285A (https=)
MX (1) MX2021011040A (https=)
SG (1) SG11202108761YA (https=)
TW (1) TWI901581B (https=)
WO (1) WO2020182974A1 (https=)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI869528B (zh) 2020-01-13 2025-01-11 美商威特拉公司 C5ar1抗體分子及其用途
WO2022057910A1 (en) * 2020-09-17 2022-03-24 I-Mab Biopharma Co., Ltd Combination therapies targeting c5ar and pd-1/pd-l1 pathways
CA3173944A1 (en) 2021-01-13 2022-07-21 Visterra, Inc. Humanized complement 5a receptor 1 antibodies and methods of use thereof
WO2024236163A1 (en) 2023-05-17 2024-11-21 Morphosys Ag T cell receptor beta constant region 2 (trbc2) antibodies

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1642983A (zh) * 2002-01-25 2005-07-20 G2治疗有限公司 抗C5aR抗体及其应用
CN104151429A (zh) * 2007-11-26 2014-11-19 拜耳知识产权有限责任公司 抗-间皮素抗体及其用途
CN105963694A (zh) * 2010-04-30 2016-09-28 阿雷克森制药公司 抗-c5a抗体和使用所述抗体的方法

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5641870A (en) 1995-04-20 1997-06-24 Genentech, Inc. Low pH hydrophobic interaction chromatography for antibody purification
EP1958962A3 (en) 1997-06-12 2013-05-01 Novartis International Pharmaceutical Ltd. Artificial antibody polypeptides
US6136599A (en) 1998-12-10 2000-10-24 Bayer Corporation Human hybrid host cell for mammalian gene expression
ES2327382T3 (es) 1999-07-20 2009-10-29 Morphosys Ag Metodos para presentar (poli)peptidos/proteinas en particulas de bacteriofagos a traves de enlaces disulfuro.
TWI380996B (zh) 2004-09-17 2013-01-01 Hoffmann La Roche 抗ｏｘ４０ｌ抗體
RU2010138612A (ru) 2008-02-20 2012-03-27 Джи2 ИНФЛЕММЕЙШН ПТИ ЛТД (AU) ГУМАНИЗИРОВАННЫЕ АНТИТЕЛА ПРОТИВ C5аR
ES2692268T5 (en) 2011-03-29 2025-02-26 Roche Glycart Ag Antibody fc variants
DK3424953T3 (en) * 2011-06-06 2020-11-02 Novo Nordisk As Terapeutiske antistoffer
JP2016523829A (ja) * 2013-05-08 2016-08-12 ノヴォ ノルディスク アー／エス Ｃ５ａｒアンタゴニストの使用
ES2736500T3 (es) 2014-06-18 2020-01-02 Morphosys Ag Proteínas de fusión y usos de las mismas
TWI786132B (zh) 2017-06-23 2022-12-11 德商因夫萊亞斯有限公司 活性抑制劑於發炎性疾病之治療

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1642983A (zh) * 2002-01-25 2005-07-20 G2治疗有限公司 抗C5aR抗体及其应用
CN104151429A (zh) * 2007-11-26 2014-11-19 拜耳知识产权有限责任公司 抗-间皮素抗体及其用途
CN105963694A (zh) * 2010-04-30 2016-09-28 阿雷克森制药公司 抗-c5a抗体和使用所述抗体的方法

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
Analysis of C5a receptor by monoclonal antibody;H Watanabe;《Journal of Immunoogical Methods》;第185卷(第1期);第19-29页 *
Blockade of the C5a-C5aR axis alleviates lung damage in hDPP4-transgenic mice infected with MERS-CoV;Yuting Jiang;《Emerging Microbes Infecttions》;第7卷(第1期);第1-12页 *
C5a receptor (CD88) blockade protects against MPO-ANCA GN;Hong Xiao;《Journal of the American Society of Nephrology》;第25卷(第2期);第225-231页 *
Genbank.Accession No.: ABC67025.1,immunoglobulin light chain variable region YM2-PPS-14-L1-28, partial [Homo sapiens].《Genbank》.2016,Features. *

Also Published As

Publication number Publication date
JP7617012B2 (ja) 2025-01-17
JP7842914B2 (ja) 2026-04-08
TW202041535A (zh) 2020-11-16
AU2020235263A1 (en) 2021-09-02
NZ778810A (en) 2025-10-31
CN113574072A (zh) 2021-10-29
EP3938393A1 (en) 2022-01-19
WO2020182974A1 (en) 2020-09-17
US20240400657A1 (en) 2024-12-05
SG11202108761YA (en) 2021-09-29
JP2022524449A (ja) 2022-05-02
JP2025069140A (ja) 2025-04-30
IL286238A (en) 2021-10-31
BR112021017860A2 (pt) 2021-12-07
TWI901581B (zh) 2025-10-21
US20240018225A1 (en) 2024-01-18
KR20210141988A (ko) 2021-11-23
US12018072B2 (en) 2024-06-25
MX2021011040A (es) 2021-12-10
CA3132771A1 (en) 2020-09-17
US20220135658A1 (en) 2022-05-05
MA55285A (fr) 2022-01-19

Similar Documents

Publication Publication Date Title
CN113248618B (zh) 抗pd-l1/抗lag3双特异性抗体及其用途
CA2850549C (en) Antibodies against tl1a and uses thereof
AU2014214530B2 (en) IL-11R binding proteins and uses thereof
EP3538557A2 (en) Anti-cd47 antibodies
KR101822702B1 (ko) G-csfr에 대한 항체 및 이의 용도
KR20210143192A (ko) 변형된 Fc 단편, 이를 포함하는 항체 및 이의 응용
JP7842914B2 (ja) Ｃ５ａＲを標的とする抗体
CA2998350A1 (en) Anti-cd115 antibodies
KR20210076918A (ko) 4-1bb 및 종양-관련 항원에 결합하는 항체 작제물 및 이의 용도
JP2023506465A (ja) 抗ＭｅｒＴＫ抗体及びその使用方法
AU2016361462A1 (en) CD131 binding proteins and uses thereof
CA3096791A1 (en) Cell engaging binding molecules
CN118055946A (zh) 新型多特异性分子
US20250059288A1 (en) Antibodies targeting ccr2
CN119300858A (zh) 抗原结合蛋白
CA3254085A1 (en) KLRB1 LIAISON AGENTS AND THEIR METHODS OF USE
RU2823245C2 (ru) Антитела, нацеливающиеся на C5aR
KR20230087552A (ko) Cd45를 다량체화하는 결합 분자
HK40061359A (en) Antibodies targeting c5ar
HK40061359B (zh) 靶向c5ar的抗体
WO2025190376A1 (zh) 抗cd161抗体及其用途
WO2025190375A1 (zh) 抗cd161抗体及其用途
WO2025185656A1 (zh) 抗pd-l1和cd40双特异性抗体及其用途
HK40057471A (en) Anti-pd-l1/anti-lag3 bispecific antibody and use thereof
HK40057471B (en) Anti-pd-l1/anti-lag3 bispecific antibody and use thereof

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 40061359

Country of ref document: HK

GR01 Patent grant
GR01 Patent grant